References

  1. Lipton, R.B., Bigal, M.E., Diamond, M., Freitag, F., Reed, M.L., Stewart, W.F., AMPP Advisory Group. (2007, January 30). Migraine prevalence, disease burden, and the need for preventive therapy. Retrieved October 1, 2017 from, http://www.neurology.org/content/68/5/343.long
  2. World Health Organization (2006). Neurological disorders: public health challenges. Geneve: World Health Organization. Retrieved April 17, 2017, from http://www.who.int/mental_health/neurology/neurodiso/en/
  3. International Headache Society (2013). The International Classification of Headache Disorders, 3rd edition. Cephalgia 33(9) 629-808. Retrieved April 17, 2017, from https://www.ichd-3.org/
  4. Gasparini, C. F., Sutherland, H. G., & Griffiths, L. R. Studies on the Pathophysiology and Genetic Basis of Migraine. Current Genomics, 2013, 14, 300-315. Retrieved April 12, 2017, from https://www.semanticscholar.org/paper/Studies-on-the-Pathophysiology-and-Genetic-Basis-Gasparini-Sutherland/a960a6763aa432ea45b5970d30413abad8ad31fd
  5. Durham, P. L. (2006, June). Calcitonin Gene-Related Peptide (CGRP) and Migraine. Headache, 2006 Jun; 46 (Suppl 1): S3-S8. Retrieved April 12, 2017, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3134175/
  6. Durham, P. L., & Vause, C. V. (2010, July 01). CGRP Receptor Antagonists in the Treatment of Migraine. CNS Drugs, 2010 Jul 1; 24(7): 539-548. Retrieved April 12, 2017, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3138175
  7. Raddant, A. C., & Russo, A. F. (2011, November 29). Calcitonin gene-related peptide in migraine: intersection of peripheral inflammation and central modulation. National Institute of Health 13:36. Retrieved April 17, 2017, from https://www.ncbi.nlm.nih.gov/pubmed/22123247
  8. Kaiser, E. A., & Russo, A. F. (2013, December). CGRP and migraine: Could PACAP play a role too? Neuropeptides, 47:6. Retrieved April 17, 2017, from http://www.neuropeptidesjournal.com/article/S0143-4179(13)00076-0/references
  9. Bigal, M. E., Walter, S., & Rapoport, A. M. (2015, May 22). Therapeutic antibodies against CGRP or its receptor. British Journal of Clinical Pharmacology, 79:6 886-895. Retrieved April 17, 2017, from http://onlinelibrary.wiley.com/doi/10.1111/bcp.12591/abstract
  10. Silberstein, S. D. (2000, September 26). Practice parameter: Evidence-based guidelines for migraine headache (an evidence-based review). Neurology. Retrieved April 17, 2017, from http://www.neurology.org/content/55/6/754.full
  11. Lipton, R. B., & Silberstein, S. D. (2015, February 06). Episodic and Chronic Migraine Headache: Breaking Down Barriers to Optimal Treatment and Prevention The Journal of Head and Face Pain, 2015: 103-122. Retrieved April 12, 2017, from http://onlinelibrary.wiley.com/doi/10.1111/head.12505_2/abstract
  12. Bigal, M. E., & Lipton, R. B. (2008, September 09). Clinical course in migraine: conceptualizing migraine transformation. Neurology 71:11 848-855. Retrieved April 17, 2017, from https://www.ncbi.nlm.nih.gov/pubmed/18779513
  13. Bigal, M. E., & Lipton, R. B. (2009, August). Overuse of acute migraine medications and migraine chronification. Current Pain & Headache Reports, 13:301-307. Retrieved April 13, 2017, from https://www.ncbi.nlm.nih.gov/pubmed/19586594
  14. Antonaci, F., Ghiotto,N., Wu, S., Pucci, E., Costa, A. (2016). Recent advances in migraine therapy. Retrieved October 1, 2017 from, https://springerplus.springeropen.com/articles/10.1186/s40064-016-2211-8
  15. D'Amico, D., & Tepper, S. J. (2008, December). Prophylaxis of migraine: general principles and patient acceptance. Neuropsychiatric Disease and Treatment, 2008 Dec;4(6):1155-67. Retrieved April 13, 2017, from https://www.ncbi.nlm.nih.gov/pubmed/19337456
  16. American Academy of Neurology. (2013). PRESCRIPTION DRUG TREATMENT FOR MIGRAINE PREVENTION IN ADULTS. AAN. Retrieved April 13, 2017, from https://www.aan.com/Guidelines/Home/GetGuidelineContent/544
  17. Silberstein, Stephen D. "Preventive Migraine Treatment." Continuum : Lifelong Learning in Neurology, American Academy of Neurology, Aug. 2015, www.ncbi.nlm.nih.gov/pmc/articles/PMC4640499
  18. Hepp, Zsolt, et al. "Adherence to Oral Migraine-Preventive Medications among Patients with Chronic Migraine." Cephalalgia, SAGE Publications Ltd, 19 June 2015, mayoclinic.pure.elsevier.com/en/publications/adherence-to-oral-migraine-preventive-medications-among-patients-.
  19. Vos, Theo, et al. "Global, Regional, and National Incidence, Prevalence, and Years Lived with Disability for 310 Diseases and Injuries, 1990-2015: a Systematic Analysis for the Global Burden of Disease Study 2015." The Lancet, vol. 388, no. 10053, 2016, pp. 1545-1602., doi:10.1016/s0140-6736(16)31678-6.
  20. Messali, A., Sanderson, J.C., Blumenfeld, A.M., Goadsby, P.J., Buse, D.C., Varon, S.,F., Stokes, M., Lipton, R.B. (2016, February). Direct and Indirect Costs of Chronic and Episodic Migraine in the United States: A Web-Based Survey. Retrieved October 1, 2017 from, https://www.ncbi.nlm.nih.gov/pubmed/26833083
  21. Lipton, R., Bigal, M., Kolodner, K., Stewart, W., Liberman, J., & Steiner, T. (2003, June 13). The family impact of migraine: population‐based studies in the USA and UK. Cephalalgia, 2003. 23(6): p. 429-40. Retrieved April 17, 2017, from https://www.ncbi.nlm.nih.gov/pubmed/12807522
  22. Lipton, R. B., Stewart, W. F., Diamond, S., Diamond, M. L., & Reed, M. (2001, December 20). Prevalence and Burden of Migraine in the United States: Data From the American Migraine Study II. The Journal of Head and Face Pain 41:7 646-657. Retrieved April 17, 2017, from http://onlinelibrary.wiley.com/doi/10.1046/j.1526-4610.2001.041007646.x/abstract
  23. Lipton, Richard B., and Marcelo E. Bigal. "Migraine: Epidemiology, Impact, and Risk Factors for Progression." Headache: The Journal of Head and Face Pain, Blackwell Science Inc, 5 Apr. 2005, http://onlinelibrary.wiley.com/doi/10.1111/j.1526-4610.2005.4501001.x/abstract
  24. Giannini,G., Zanigni, S., Grimaldi, D., Melotti, R., Pierangeli, G., Cortelli, P., Cevoli, S. (2013, June 10). Cephalalgiaphobia as a feature of high-frequency migraine: a pilot study. Retrieved October 1, 2017 from, https://thejournalofheadacheandpain.springeropen.com/articles/10.1186/1129-2377-14-49
  25. "Interventional Headache Management." American Migraine Foundation, americanmigrainefoundation.org/understanding-migraine/spotlight-on-interventional-headache-management/
  26. Dodick, David W., et al. "OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double‐Blind, Randomized, Placebo‐Controlled Phases of the PREEMPT Clinical Program." Headache: The Journal of Head and Face Pain, Blackwell Publishing Inc, 7 May 2010, onlinelibrary.wiley.com/doi/10.1111/j.1526-4610.2010.01678.x/full.
  27. "Neuromodulation Devices for Headache." American Migraine Foundation, americanmigrainefoundation.org/understanding-migraine/spotlight-neuromodulation-devices-headache/